We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Trio Of Pharma Cos. Fight Post-Trial Bids In $1B Patent Row

Law360, New York (October 12, 2017, 1:56 PM EDT) -- Three pharmaceutical companies involved in a $1 billion patent infringement suit over a quality control test for a generic blood thinner contested each other’s dueling bids for post-trial relief Wednesday — including judgment or a new trial — after a jury found the patent was infringed but the claims were nonetheless invalid.

Momenta Pharmaceuticals and Sandoz Inc., which alleged the patent infringement, argued that Amphastar Pharmaceuticals' request for a ruling that it hadn’t infringed U.S. Patent Number 7,575,886 does not reflect the evidence that was presented at...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.